Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yin Gu

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Bioorganic & Medicinal Chemistry Letters|June 15, 2010
Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitorsMichael K Ameriks, Scott D Bembenek, Matthew T Burdett, et al.
Scientific Reports|August 17, 2016
Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteersYun-Xi Zhong, Xiao-Liang Jin, Shi-Yin Gu, et al.
Biosensors & Bioelectronics|November 3, 2022
An ultrasensitive and rapid "sample-to-answer" microsystem for on-site monitoring of SARS-CoV-2 in aerosols using "in situ" tetra-primer recombinase polymerase amplificationShanglin Li, Bao Li, Xinyue Li, et al.
Integrative Cancer Therapies|July 12, 2012
Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancerYan Xu, Ai Guang Zhao, Zhao Yan Li, et al.
Plos One|July 5, 2013
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA MutationDouglas D Fang, Cathy C Zhang, Yin Gu, et al.
Journal of Hematology & Oncology|May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemiaManoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
Blood Advances|January 4, 2018
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignanciesShu-Hui Liu, Yin Gu, Bernadette Pascual, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Bioorganic & Medicinal Chemistry Letters|June 15, 2010
Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitorsMichael K Ameriks, Scott D Bembenek, Matthew T Burdett, et al.
Scientific Reports|August 17, 2016
Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteersYun-Xi Zhong, Xiao-Liang Jin, Shi-Yin Gu, et al.
Biosensors & Bioelectronics|November 3, 2022
An ultrasensitive and rapid "sample-to-answer" microsystem for on-site monitoring of SARS-CoV-2 in aerosols using "in situ" tetra-primer recombinase polymerase amplificationShanglin Li, Bao Li, Xinyue Li, et al.
Integrative Cancer Therapies|July 12, 2012
Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancerYan Xu, Ai Guang Zhao, Zhao Yan Li, et al.
Plos One|July 5, 2013
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA MutationDouglas D Fang, Cathy C Zhang, Yin Gu, et al.
Journal of Hematology & Oncology|May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemiaManoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
Blood Advances|January 4, 2018
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignanciesShu-Hui Liu, Yin Gu, Bernadette Pascual, et al.
Pageof 6